You are here


Samsung Bioepis races to get biosimilar drugs on the market

Korean conglomerate hopes its biopharmaceuticals push can help offset a slowing smartphone market

Bioepis employees at its laboratory in Incheon. To quickly get up to speed in an unfamiliar industry, Samsung enlisted drugmaker Biogen as a Bioepis shareholder, scouted industry veterans from firms such as Novartis and Eli Lilly and surrounded them with young recruits.


AS Samsung Bioepis raced to be first to market with a copy of Enbrel, a blockbuster rheumatoid arthritis drug, countdown clocks reminded workers: heading for lunch, meetings or even the washroom: of the days to the first mass production run.

Founded four years ago by South...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to